Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ACAD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ACAD

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

ACADIA Pharmaceuticals Inc

ACAD
Current price
22.55 USD +0.47 USD (+2.13%)
Last closed 22.01 USD
ISIN US0042251084
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 692 005 632 USD
Yield for 12 month +22.89 %
1Y
3Y
5Y
10Y
15Y
ACAD
21.11.2021 - 28.11.2021

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. Address: 12830 El Camino Real, San Diego, CA, United States, 92130

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

28.47 USD

P/E Ratio

16.10

Dividend Yield

Financials ACAD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ACAD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+957 797 000 USD

Last Year

+726 437 000 USD

Current Quarter

+244 317 000 USD

Last Quarter

+259 602 000 USD

Current Year

+875 956 000 USD

Last Year

+680 706 000 USD

Current Quarter

+223 925 000 USD

Last Quarter

+237 799 000 USD
EBITDA 101 665 000 USD
Operating Margin TTM 7.90 %
Price to Earnings 16.10
Return On Assets TTM 5.56 %
PEG Ratio -0.42
Return On Equity TTM 37.24 %
Wall Street Target Price 28.47 USD
Revenue TTM 996 283 008 USD
Book Value 4.58 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 18.70 %
Dividend Yield
Gross Profit TTM 595 166 016 USD
Earnings per share 1.37 USD
Diluted Eps TTM 1.37 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 10.00 %
Profit Margin 22.97 %

Stock Valuation ACAD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 16.10
Forward PE 49.02
Enterprise Value Revenue 3.00
Price Sales TTM 3.71
Enterprise Value EBITDA 29.36
Price Book MRQ 4.72

Technical Indicators ACAD

For 52 Weeks

13.40 USD 25.23 USD
50 Day MA 20.36 USD
Shares Short Prior Month 15 435 884
200 Day MA 17.68 USD
Short Ratio 6.15
Shares Short 12 825 369
Short Percent 14.53 %